Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT01083342
Other study ID # 2009-12-087
Secondary ID
Status Completed
Phase Phase 2
First received March 8, 2010
Last updated May 22, 2012
Start date January 2010
Est. completion date May 2012

Study information

Verified date May 2012
Source Samsung Medical Center
Contact n/a
Is FDA regulated No
Health authority Korea: Food and Drug Administration
Study type Interventional

Clinical Trial Summary

The purpose of this study is to evaluate the complete response (CR) rate after HD-MTX induction chemotherapy followed by alternative HD MTX-based and HD Cytarabine-based combination consolidation chemotherapy


Read more »

Study Design

Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment


Related Conditions & MeSH terms


Intervention

Drug:
MTX, MVD, VIA
MTX: Methotrexate,Leucovorin MVD: Methotrexate,Vincristine,Dexamethasone VIA: VP-16 (Etoposide),Ifosfamide,Mesna, Cytarabine (ara-C)

Locations

Country Name City State
Korea, Republic of Samsung Medical Center Seoul

Sponsors (1)

Lead Sponsor Collaborator
Samsung Medical Center

Country where clinical trial is conducted

Korea, Republic of, 

Outcome

Type Measure Description Time frame Safety issue
Primary To evaluate the complete response (CR) after chemotherapy 24 months Yes
Secondary To evaluate the duration of response 24 months Yes
Secondary To evaluate the progression-free survival, overall survival 24 months Yes
Secondary To evaluate the safety profiles 24 months Yes
See also
  Status Clinical Trial Phase
Recruiting NCT05117814 - Zanubrutinib Monotherapy in Relapsed/Refractory Central Nervous System Lymphoma N/A
Terminated NCT05222269 - [68Ga]Ga-PentixaFor PET Imaging in CNS Lymphoma Patients Phase 2
Recruiting NCT06132737 - [90Y]Y-PTT Endoradiotherapy in CNS Lymphoma Patients Phase 1/Phase 2
Terminated NCT05242146 - GB5121 in Adult Patients With Relapsed/Refractory CNS Lymphoma Phase 1
Completed NCT01319591 - Comparison of Creatinine Clearance Calculation for Estimation of GFR in Patients Receiving HD Methotrexate
Recruiting NCT06322342 - Phase 2 Ascending Dose Safety and Efficacy Study of RVP-001, a Manganese-based MRI Contrast Agent Phase 2
Recruiting NCT05351593 - Tafasitamab Plus Lenalidomide in Relapsed CNS Lymphoma Phase 1/Phase 2
Not yet recruiting NCT05828628 - CLIMB: CNS Lymphoma Imaging and Molecular Biomarkers Study
Completed NCT01182415 - High Dose Chemotherapy and Stem Cell Transplant for Non-Hodgkin's Lymphoma or Central Nervous System (CNS) Lymphoma Phase 2
Not yet recruiting NCT06343311 - T-Cell Therapy (EB103) in Adults With Relapsed/Refractory B-Cell Non-Hodgkin's Lymphoma (NHL) Phase 1/Phase 2
Recruiting NCT04841434 - A Phase I/II Study to Investigate the Use of VORAXAZE™ as Intended Intervention in Patients With CNSL Phase 1/Phase 2
Completed NCT05293990 - Usefulness of Gadovist-enhanced FLAIR Imaging N/A
Completed NCT00596154 - Rituximab, Methotrexate, Procarbazine and Vincristine Followed by High-dose Chemotherapy With Autologous Stem-cell Rescue in Newly-diagnosed Primary CNS Lymphoma Phase 2
Recruiting NCT05926427 - Orelabrutinib Combined With Rituximab and Chemotherapy for Relapsed/Refractory B-Cell Lymphoma Patients With Central Nervous System Involvement Phase 2